# TAF Switch Study in Hepatitis B Monoinfection

> **NCT02957994** · PHASE4 · UNKNOWN · sponsor: **Asian Pacific Liver Center at Coalition of Inclusive Medicine** · enrollment: 82 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Tenofovir alafenamide fumarate

## Key facts

- **NCT ID:** NCT02957994
- **Lead sponsor:** Asian Pacific Liver Center at Coalition of Inclusive Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12-22
- **Primary completion:** 2017-06-21
- **Final completion:** 2017-11-01
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2017-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02957994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02957994, "TAF Switch Study in Hepatitis B Monoinfection". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT02957994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*